Supported by the U.S. Operation Warp Speed program; the National Institute of Allergy and Infectious Diseases and Leidos Biomedical Researchfor the INSIGHT Network; the National Heart, Lung, and Blood Institute and the Research Triangle Institute for the PETAL (Prevention and Early Treatment of Acute Lung Injury) Network and the Cardiothoracic Surgical Trials Network; and the U.S. Department of Veterans Affairs and grants from the governments of Denmark (no. 126 from the National Research Foundation), Australia (from the National Health and Medical Research Council), and the United Kingdom (MRC_UU_12023/23 from the Medical Research Council). Trial medications were donated by Gilead Sciences and Eli Lilly.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
The members of the writing committee are as follows: Prof. Jens D. Lundgren, M.D., D.M.Sc., Birgit Grund, Ph.D., Christina E. Barkauskas, M.D., Thomas L. Holland, M.D., Robert L. Gottlieb, M.D., Ph.D., Uriel Sandkovsky, M.D., Samuel M. Brown, M.D., Kirk U. Knowlton, M.D., Wesley H. Self, M.D., M.P.H., D. Clark Files, M.D., Mamta K. Jain, M.D., M.P.H., Thomas Benfield, M.D., D.M.Sc., Michael E. Bowdish, M.D., Bradley G. Leshnower, M.D., Jason V. Baker, M.D., Jens-Ulrik Jensen, M.D., Ph.D., Edward M. Gardner, M.D., Adit A. Ginde, M.D., M.P.H., Estelle S. Harris, M.D., Isik S. Johansen, M.D., D.M.Sc., Norman Markowitz, M.D., Michael A. Matthay, M.D., Lars Østergaard, M.D., Ph.D., D.M.Sc., Christina C. Chang, M.D., Ph.D., Victoria J. Davey, Ph.D., M.P.H., Anna Goodman, F.R.C.P., D.Phil., Elizabeth S. Higgs, M.D., Daniel D. Murray, Ph.D., Thomas A. Murray, Ph.D., Roger Paredes, M.D., Ph.D., Mahesh K.B. Parmar, Ph.D., Andrew N. Phillips, Ph.D., Cavan Reilly, Ph.D., Shweta Sharma, M.S., Robin L. Dewar, Ph.D., Marc Teitelbaum, M.D., Deborah Wentworth, M.P.H., Huyen Cao, M.D., Paul Klekotka, M.D., Ph.D., Abdel G. Babiker, Ph.D., Annetine C. Gelijns, Ph.D., Virginia L. Kan, M.D., Mark N. Polizzotto, M.D., Ph.D., B. Taylor Thompson, M.D., H. Clifford Lane, M.D., and James D. Neaton, Ph.D.
This article was published on December 22, 2020, at NEJM.org.
A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.
We thank the members of the TICO data and safety monitoring board — Merlin L. Robb, M.D. (chair), David Glidden, Ph.D., Graeme A. Meintjes, M.B., Ch.B., Ph.D., Barbara E. Murray, M.D., Stuart Campbell Ray, M.D., Valeria Cavalcanti Rolla, M.D., Ph.D., Haroon Saloojee, M.B., B.Ch., Anastasios A. Tsiatis, Ph.D., Paul A. Volberding, M.D., Jonathan Kimmelman, Ph.D., and Sally Hunsberger, Ph.D. (executive secretary) — for their review of the protocol and their guidance based on interim reviews of the data.
The Link LonkDecember 23, 2020 at 05:00AM
https://ift.tt/38vthMe
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 - nejm.org
https://ift.tt/3d5QSDO
No comments:
Post a Comment